Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Combined With Fractionated Radiotherapy in Recurrent Glioblastoma
NCT05737368Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Bispecific Antibodies
01
Overview
Phase 1, open-label, single-arm trial of cadonilimab in glioblastoma (GBM), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence and severity of adverse events at 3 months. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05737368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737368.